ASH Annual Meeting and Exposition | Conference

Axi-Cel Efficacy Persists at 2-Year Assessment for Large B-Cell Lymphoma

December 4th 2018

Axicabtagene ciloleucel elicited a 2-year overall survival rate of 51% in patients with refractory large B cell lymphoma, representing a clear plateau in the survival curve.

Quizartinib Update Presented as FDA Weighs AML Approval

December 4th 2018

The overall survival benefit with quizartinib in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia was observed across patient subgroups and reproduced consistently across sensitivity analyses.

Phase III Data Showcase PFS Benefit With Frontline Ibrutinib/Obinutuzumab Combo in High-Risk CLL

December 4th 2018

The first-line combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) was associated with a 77% reduction in the risk for disease progression or death compared with chemoimmunotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Acalabrutinib Monotherapy Produces Durable Response in Mantle Cell Lymphoma

December 4th 2018

Long-term follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma shows that responses are durable with no new safety signals observed.

Lenalidomide/Rituximab Improves PFS in Indolent Non-Hodgkin Lymphoma

December 3rd 2018

The R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) reduced the risk of disease progression or death by 54% versus rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Antibody-Drug Conjugate Impresses in Relapsed/Refractory DLBCL

December 3rd 2018

The addition of a CD79b-targeted antibody-drug conjugate to bendamustine and rituximab more than doubled overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma.

Venetoclax With HMAs Shows Promise in AML for Patients Ineligible for High-Dose Chemo

December 3rd 2018

More than 70% of older patients ineligible for intensive chemotherapy for acute myeloid leukemia had complete responses to venetoclax combined with hypomethylating agents, preliminary results from clinical trials have shown.

Next-Generation BCMA CAR T-cell Therapy Effective for Heavily Pretreated Myeloma

December 3rd 2018

The anti-BCMA CAR T cell therapy bb21217 demonstrated an objective response rate of 83.3%, with a very good partial response or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma.

New Prediction Model Improves Personalized Insight Into MDS Survival

December 3rd 2018

An approach using machine learning to analyze genomic and clinical data from patients with myelodysplastic syndromes could replace the gold standard of predicting how long patients may live with the disease.

Dr. Leonard on AUGMENT Trial Results in Non-Hodgkin Lymphoma

December 3rd 2018

John P. Leonard, MD, associate dean for clinical research and Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, discusses the key takeaway from the phase III AUGMENT trial, a randomized study of lenalidomide (Revlimid) plus rituximab (Rituxan) (R2) versus rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma, during the 2018 ASH Annual Meeting.

Dr. Gauthier on Findings for CD19-Targeted CAR T Cells Plus Ibrutinib in CLL

December 3rd 2018

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses a study comparing efficacy and toxicity of CD19-specific chimeric antigen receptor (CAR) T cells alone or in combination with ibrutinib in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) during the 2018 ASH Annual Meeting.

Mosunetuzumab Shows Promise for Non-Hodgkin Lymphoma

December 3rd 2018

The CD3 and CD20 bispecific antibody mosunetuzumab demonstrated promising complete remission rates with tolerable toxicity for patients with relapsed/refractory B-cell indolent and aggressive non-Hodgkin lymphoma.

Anti-PD-1 Plus Umbralisib/Ublituximab Hits 90% Response in CLL

December 3rd 2018

The triplet regimen of pembrolizumab (Keytruda) plus umbralisib and ublituximab reached a 90% response rate in patients with relapsed/refractory chronic lymphocytic leukemia.

Beat AML Trial Proves Feasibility of Rapid Treatment Assignment Following Diagnosis

December 3rd 2018

Initial findings from the Beat AML study showed that rapid genetic testing in patients with AML was feasible and helpful, and that a precision medicine approach is possible for these patients, who must be treated urgently given the disease’s rapid progression.

Liso-Cel Demonstrates Durable Responses in Heavily Pretreated, High-Risk CLL

December 3rd 2018

Lisocabtagene maraleucel appeared tolerable and induced an 81.3% best overall response rate and 43.8% complete response rate in heavily pretreated, high-risk patients with chronic lymphocytic leukemia who previously received ibrutinib.

Ibrutinib Efficacy Sustained at 7-Year Analysis for CLL

December 3rd 2018

Single-agent ibrutinib continued to demonstrate strong results after 7 years of follow-up in both the frontline and heavily pretreated, relapsed/refractory setting for patients with CLL and SLL.

Maintenance Ixazomib Extends PFS in Newly Diagnosed Multiple Myeloma

December 3rd 2018

Two-year maintenance therapy with ixazomib led to a 39% improvement in progression-free survival compared with placebo in patients with newly diagnosed multiple myeloma who achieved a partial response to induction treatment with a proteasome inhibitor and/or an immunomodulatory agent following autologous stem cell transplant.

Ibrutinib/Venetoclax Combination Achieves High Rate of MRD Negativity in Relapsed/Refractory CLL

December 3rd 2018

The combination of ibrutinib and venetoclax is well tolerated and eradicates minimal residual disease in the marrow after 12 months in 39% of patients with relapsed/refractory chronic lymphocytic leukemia.

Zanubrutinib Highly Active in Relapsed/Refractory MCL

December 2nd 2018

The investigational agent zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor, is highly active in patients with relapsed/refractory mantle cell lymphoma.

Checkpoint Inhibition May Improve CAR T-Cell Persistence

December 2nd 2018

Checkpoint inhibition showed promise for augmenting or extending response to chimeric antigen receptor T-cell therapy in some patients with relapsed B-cell acute lymphoblastic leukemia.